Verastem Inc (VSTM)
11.66
-0.18
(-1.52%)
USD |
NASDAQ |
May 07, 15:20
Verastem Research and Development Expense (Quarterly): 22.50M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 22.50M |
| September 30, 2023 | 13.95M |
| June 30, 2023 | 12.89M |
| March 31, 2023 | 12.02M |
| December 31, 2022 | 10.74M |
| September 30, 2022 | 11.29M |
| June 30, 2022 | 14.89M |
| March 31, 2022 | 13.64M |
| December 31, 2021 | 11.40M |
| September 30, 2021 | 9.325M |
| June 30, 2021 | 9.73M |
| March 31, 2021 | 8.896M |
| December 31, 2020 | 10.15M |
| September 30, 2020 | 10.96M |
| June 30, 2020 | 9.344M |
| March 31, 2020 | 10.92M |
| December 31, 2019 | 12.46M |
| September 30, 2019 | 12.22M |
| June 30, 2019 | 11.35M |
| March 31, 2019 | 9.758M |
| December 31, 2018 | 8.762M |
| September 30, 2018 | 11.57M |
| June 30, 2018 | 12.38M |
| March 31, 2018 | 10.93M |
| December 31, 2017 | 11.25M |
| Date | Value |
|---|---|
| September 30, 2017 | 17.74M |
| June 30, 2017 | 9.042M |
| March 31, 2017 | 8.385M |
| December 31, 2016 | 6.892M |
| September 30, 2016 | 4.216M |
| June 30, 2016 | 4.492M |
| March 31, 2016 | 4.179M |
| December 31, 2015 | 7.688M |
| September 30, 2015 | 11.30M |
| June 30, 2015 | 11.04M |
| March 31, 2015 | 10.53M |
| December 31, 2014 | 9.685M |
| September 30, 2014 | 9.047M |
| June 30, 2014 | 8.305M |
| March 31, 2014 | 8.411M |
| December 31, 2013 | 7.80M |
| September 30, 2013 | 6.789M |
| June 30, 2013 | 6.045M |
| March 31, 2013 | 5.296M |
| December 31, 2012 | 4.094M |
| September 30, 2012 | 8.132M |
| June 30, 2012 | 4.683M |
| March 31, 2012 | 4.803M |
| December 31, 2011 | 4.40M |
| September 30, 2011 | 3.082M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.896M
Minimum
Mar 2021
22.50M
Maximum
Dec 2023
12.03M
Average
11.35M
Median
Jun 2019
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.542B |
| Geron Corp | 29.37M |
| Altimmune Inc | 16.91M |
| Oragenics Inc | 11.04M |
| Actinium Pharmaceuticals Inc | 6.635M |